Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019

NEXT STORY
RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING INCOME +4.9%, NET INCOME +6.6%. INTERIM DIVIDEND € 0.48 (+6.7%).
PREV STORY
Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OraSure Receives $205 Million Procurement Contract for InteliSwab™ from the Defense Logistics Agency to Supply Over-the-Counter (OTC) Kits as Part of National Pandemic Response

author_avatar
NASDAQ Market News

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

author_avatar
NASDAQ Market News

Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress

author_avatar
NASDAQ Market News